Highlights and News

(PDF) Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial - ResearchGate

(PDF) Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial  ResearchGate

Deciphering the molecular landscape of rheumatoid arthritis offers new insights into the stratified treatment for the condition - Frontiers

Deciphering the molecular landscape of rheumatoid arthritis offers new insights into the stratified treatment for the condition  Frontiers

Automated multi-scale computational pathotyping (AMSCP) of inflamed synovial tissue - Nature.com

Automated multi-scale computational pathotyping (AMSCP) of inflamed synovial tissue  Nature.com

Clinical implications of synovial tissue phenotypes in rheumatoid arthritis - Frontiers

Clinical implications of synovial tissue phenotypes in rheumatoid arthritis  Frontiers

Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials - The Lancet

Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials  The Lancet

Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK - The BMJ

Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK  The BMJ

Clinical outcomes over 2 years. Mean Clinical Disease Activity Index... - ResearchGate

Clinical outcomes over 2 years. Mean Clinical Disease Activity Index...  ResearchGate

Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial - Nature.com

Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial  Nature.com

Oral Presentation Abstracts - 2024 - International Journal of Rheumatic Diseases - Wiley Online Library

Oral Presentation Abstracts - 2024 - International Journal of Rheumatic Diseases  Wiley Online Library

Towards stratified treatment of JIA: machine learning identifies subtypes in response to methotrexate from four UK cohorts - The Lancet

Towards stratified treatment of JIA: machine learning identifies subtypes in response to methotrexate from four UK cohorts  The Lancet

Are innovation and new technologies in precision medicine paving a new era in patients centric care? - Journal of Translational Medicine

Are innovation and new technologies in precision medicine paving a new era in patients centric care?  Journal of Translational Medicine

Utility of Baseline Transcriptomic Analysis of Rheumatoid Arthritis Synovium as an Indicator for Long-Term Clinical Outcomes - Frontiers

Utility of Baseline Transcriptomic Analysis of Rheumatoid Arthritis Synovium as an Indicator for Long-Term Clinical Outcomes  Frontiers

(PDF) Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials - ResearchGate

(PDF) Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials  ResearchGate

Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics - Nature.com

Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics  Nature.com

Rheumatoid arthritis - The Lancet

Rheumatoid arthritis  The Lancet

Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy - Frontiers

Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy  Frontiers

Persistence of Mast Cell-Positive Synovitis in Early Rheumatoid Arthritis Following Treatment With Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs - Frontiers

Persistence of Mast Cell-Positive Synovitis in Early Rheumatoid Arthritis Following Treatment With Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs  Frontiers